Trends in molecular epidemiology of drug-resistant tuberculosis in Republic of Karelia, Russian Federation
- PMID: 26679959
- PMCID: PMC4683759
- DOI: 10.1186/s12866-015-0613-3
Trends in molecular epidemiology of drug-resistant tuberculosis in Republic of Karelia, Russian Federation
Abstract
Background: Russian Republic of Karelia is located at the Russian-Finnish border. It contains most of the historical Karelia land inhabited with autochthonous Karels and more recently migrated Russians. Although tuberculosis (TB) incidence in Karelia is decreasing, it remains high (45.8/100 000 in 2014) with the rate of multi-drug resistance (MDR) among newly diagnosed TB patients reaching 46.5 %. The study aimed to genetically characterize Mycobacterium tuberculosis isolates obtained at different time points from TB patients from Karelia to gain insight into the phylogeographic specificity of the circulating genotypes and to assess trends in evolution of drug resistant subpopulations.
Methods: The sample included 150 M. tuberculosis isolates: 78 isolated in 2013-2014 ("new" collection) and 72 isolated in 2006 ("old" collection). Drug susceptibility testing was done by the method of absolute concentrations. Spoligotyping was used to test genotype-specific markers of a Latin-American-Mediterranean (LAM) family and its sublineages as well as a Beijing B0/W148-cluster.
Results: The largest spoligotypes were SIT1 (Beijing family, n = 42) and SIT40 (T family, n = 5). Beijing family was the largest (n = 43) followed by T (n = 11), Ural (n = 10) and LAM (n = 8). Successful Russian clone, Beijing В0/W148, was identified in 15 (34.9 %) of 43 Beijing isolates; all В0/W148 isolates were drug-resistant. Seven of 8 LAM isolates belonged to the RD115/LAM-RUS branch, 1 - to the LAM RD174/RD-Rio sublineage. MDR was found in Beijing (32/43), Ural (3/10), and LAM (3/8). In contrast, all T isolates were pansusceptible. Comparison of drug resistant subgroups of the new and old collections showed an increasing prevalence of the B0/W148 clonal cluster, from 18.0 % (mainly polyresistant) in 2006 to 32.6 % in 2014 (mainly MDR and pre-XDR). The West-east increasing gradient is observed for the Ural genotype that may be defined a 'Russian' strain. In contrast, the spoligotype SIT40 of the T family appears to be a historical Karelian strain.
Conclusions: Circulation of the MDR M. tuberculosis isolates of the Beijing genotype and its B0/W148 cluster continues to critically influence the current situation with the MDR-TB control in northwestern Russia including the Republic of Karelia. Revealed phylogeographic patterns of some genotypes reflect a complex demographic history of Karelia within the course of the 20(th) century.
Figures


Similar articles
-
Molecular structure of Mycobacterium tuberculosis population in Russia and its interaction with neighboring countries.Int J Mycobacteriol. 2015 Mar;4 Suppl 1:56-7. doi: 10.1016/j.ijmyco.2014.08.002. Epub 2014 Sep 3. Int J Mycobacteriol. 2015. PMID: 27128618
-
Emerging resistant clones of Mycobacterium tuberculosis in a spatiotemporal context.J Antimicrob Chemother. 2018 Feb 1;73(2):325-331. doi: 10.1093/jac/dkx372. J Antimicrob Chemother. 2018. PMID: 29092043
-
Spatiotemporal dynamics of drug-resistant Mycobacterium tuberculosis: Contrasting trends and implications for tuberculosis control in EU high-priority country.Transbound Emerg Dis. 2021 Mar;68(2):896-906. doi: 10.1111/tbed.13758. Epub 2020 Aug 10. Transbound Emerg Dis. 2021. PMID: 32737943
-
Insights into the origin, emergence, and current spread of a successful Russian clone of Mycobacterium tuberculosis.Clin Microbiol Rev. 2013 Apr;26(2):342-60. doi: 10.1128/CMR.00087-12. Clin Microbiol Rev. 2013. PMID: 23554420 Free PMC article. Review.
-
[Resistance to first-line drugs and major genotypic lineages of Mycobacterium tuberculosis in the 3 French Department of the Americas: Profiles, evolution, and trends (1995-2011)].Bull Soc Pathol Exot. 2014 May;107(2):90-105. doi: 10.1007/s13149-014-0339-8. Epub 2014 Mar 13. Bull Soc Pathol Exot. 2014. PMID: 24627041 Review. French.
Cited by
-
The EIMB Hydrogel Microarray Technology: Thirty Years Later.Acta Naturae. 2018 Oct-Dec;10(4):4-18. Acta Naturae. 2018. PMID: 30713758 Free PMC article.
-
Russian-United States vaccine science diplomacy: Preserving the legacy.PLoS Negl Trop Dis. 2017 May 25;11(5):e0005320. doi: 10.1371/journal.pntd.0005320. eCollection 2017 May. PLoS Negl Trop Dis. 2017. PMID: 28542186 Free PMC article. No abstract available.
-
A multifaceted interplay between virulence, drug resistance, and the phylogeographic landscape of Mycobacterium tuberculosis.Microbiol Spectr. 2023 Sep 28;11(5):e0139223. doi: 10.1128/spectrum.01392-23. Online ahead of print. Microbiol Spectr. 2023. PMID: 37768091 Free PMC article.
-
A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, Russia.PLoS One. 2016 Nov 30;11(11):e0167093. doi: 10.1371/journal.pone.0167093. eCollection 2016. PLoS One. 2016. PMID: 27902737 Free PMC article.
-
Genomic Analysis of Multidrug-Resistant Mycobacterium tuberculosis Strains From Patients in Kazakhstan.Front Genet. 2021 Nov 9;12:683515. doi: 10.3389/fgene.2021.683515. eCollection 2021. Front Genet. 2021. PMID: 34858467 Free PMC article.
References
-
- Markelov YM. Clinical and epidemiological features multidrug-resistant and the reasons for its spread in the Republic of Karelia. St. Petersburg: D.Sc. Thesis; 2011.
-
- Markelov Y, Narvskaya O. Circulation of multidrug-resistant tuberculosis pathogen strains in the Republic of Karelia. Probl. Tuberk. Bolezn. Legk. 2010;2:54–56. - PubMed
-
- The Official Karelia. http://www.gov.karelia.ru/News/2012/05/0528_12_e.html. Accessed 19 November 2015.
-
- Eskelinen H, Alanen A. Migration from Russia to Eastern Finland. Trudy Karelskogo nauchnogo Centra RAS. 2012;6:43–47.
-
- WHO 2012. Updated critical concentrations for first-line and second-line DST (as of May 2012) WHO-Stop TB Programme, Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs WHO/HTM/TB/2008.392. World Health Organisation, Geneva. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous